Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

UWC reported for 9 months of 2023 by RAS

12/15/23 UWGN

TCS Group redomiciles to Russia

12/14/23 T

Sovcombank's IPO went over the top

12/14/23 SVCB

Fesco will create direct container communication between Tashkent and Moscow

12/14/23 FESH

Ozon will launch a platform to search for trucking companies

12/14/23 OZON

SPB Exchange plans to develop the derivatives market

12/14/23 SPBE

Genetico reported for 9 months 2023 by RAS

12/13/23 GECO

Aeroflot's passenger turnover in November increased by 38.3%

12/13/23 AFLT

Shareholders of European Eltech approved dividends and buyback

12/13/23 EELT

RusAgro argued with the co-owners of Agro-Belogorye

12/13/23 RAGR